The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation (AdAPT)
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Sponsor: Jazz Pharmaceuticals
Terminated
terminated due to low enrollment rate
Other terminated trials from Jazz Pharmaceuticals
Listed as NCT03339401, this PHASE2 trial focuses on Adenovirus and remains terminated or withdrawn. Sponsored by Jazz Pharmaceuticals, it has been updated 17 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
17 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
▶ Show 12 earlier versions
-
Feb 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Terminated PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE2
-
Aug 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — May 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jazz Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .